The analysis of consumption of intestinal anti-inflammatory agents in different countries of the world
Keywords:intestinal anti-inflammatory agents, assortment of drugs, pharmaceutical market, ATC/DDD methodology, consumption of drugs
Aim. To assess drug consumption of the group A07E “Intestinal anti-inflammatory agents” in Ukraine and European countries in 2015-2017.
Materials and methods. Data from the “Pharmexplorer” information system of Morion company were used to analyze the assortment and the consumption volumes of intestinal anti-inflammatory agents in Ukraine. The volumes, structure and dynamics of drug consumption of this group in Ukraine was assessed based on the number of the consumed defined daily doses (DDD) of drugs using the ATC/DDD methodology and the number of packs sold. The level of consumption of the drugs studied by the indicator “DDDs/1000 inhabitants/day” in the countries of Europe was determined by the statistical data of these countries.
Results. The intestinal anti-inflammatory agents were presented in Ukraine in 2015-2017 in the number of 4 international non-patented names, 22-27 trade names (TN), mainly of foreign production with a high price for a pack. The number of TNs of drugs of this group and volumes of their consumption (by the number of packs sold and the number of the consumed DDDs) increased in Ukraine from 2015 to 2017. The largest number of packs sold was determined for sulfasalazine. The level of consumption of intestinal anti inflammatory agents by the indicator “DDDs/1000 inhabitants/day” in Ukraine did not correspond tothe level of drug consumption of this group in European countries (Norway, Lithuania, Latvia, Estonia) in2015-2017, and it was the lowest among the countries studied. The largest volumes of drug consumption ofthis group were determined in Norway. Mesalazine was ranked first by the number of the consumed DDDsin Norway, Lithuania and Estonia in 2015-2017, and sulfasalazine – in Latvia. The leadership of sulfasalazineand mesalazine varied over the years in Ukraine.
Conclusions. The volumes of drug consumption of the group A07E “Intestinal anti-inflammatory agents” by the number of packs sold and the number of the consumed DDDs increased in Ukraine from 2015 to 2017. The level of drug consumption of this group by the indicator “DDDs/1000 inhabitants/day” in Ukraine during 2015-2017 did not correspond to the level of consumption of the intestinal anti-inflammatory agentsin European countries.
Stepanov, Yu. M., Stoikevych, M. V., Sorochan, O. V. (2016). Hastroenterolohiia, 3 (61), 80-87.
MOZ Ukrainy. (2016). Nakaz No. 90 vid 11.02.2016 “Pro zatverdzhennia ta vprovadzhennia medykotekhnolohichnykh dokumentiv zi standartyzatsii medychnoi dopomohy pryzapalnykh zakhvoriuvanniakh kyshechnyka. Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy “Zapalni zakhvoriuvannia kyshechnyka (khvoroba Krona, vyrazkovyi kolit)”. www.mtd.dec.gov.ua. Available at: http://mtd.dec.gov.ua/images/dodatki/2016_90_Krona/2016_90_YKPMD_Kron.pdf.
Stepanov, Yu. M., Skyrda, I. Yu., Petishko, O. P. (2017). Hastroenterolohiia, 51 (2), 97-105.
Stepanov, Yu. M., Psareva, I. V. (2017). Hastroenterolohiia, 51 (1), 56-63.
Radchenko, O. M. (2015). Racional’naia farmakoterapiia, 2 (35), 5-10.
Hronicheskie vospalitel’nye zabolevanija kishechnika: kak povysit’ jeffektivnost’ lechenija i predupredit’ razvitie kolorektal’nogo raka? (2016) Zdorovia Ukrainy, Lystopad (Tematychnyi nomer), 44-46. Available at: http://health-ua.com/wp-content/uploads/2017/01/46-44.pdf.
Kushnir, I. E. (2016). Suchasna hastroenterolohiia, 4 (90), 108-115.
Bereznitskii, Ya. S., Gaponov, V. V., Sulima, V. F., Malinowski, S. L., Yushchenko, I. V., Zhmurenko, E. V. (2015). Kharkivska khirurhichna shkola, 4 (73), 174-176.
Copyright (c) 2019 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).